AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects

European Journal of Pharmaceutical Sciences

Volumn 50, Issue 3-4, 2013, Pages 440-446

  Kaplan, Nachum ^a   Garner, Colin ^b,c   Hafkin, Barry ^a  

^a Affinium Pharmaceuticals Inc   (Canada)

^b Xceleron Ltd   (United Kingdom)

^c Garner Consulting Services   (United Kingdom)

Author keywords

ADME; AFN 1252; FabI inhibitor; Phase 0; Staphylococcus aureus

Indexed keywords

AFN 1252; FATTY ACID SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MICRODOSE; DRUG SOLUBILITY; FECES; FIRST PASS EFFECT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTESTINE ABSORPTION; MALE; NONHUMAN; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIOACTIVITY; RAT;

ADME; AFN-1252; FABI INHIBITOR; PHASE 0; STAPHYLOCOCCUS AUREUS;

ABSORPTION; ADOLESCENT; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; BENZOFURANS; BLISTER; CACO-2 CELLS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; HUMANS; INTESTINES; MALE; MIDDLE AGED; PLASMA; PYRONES; RATS; RATS, SPRAGUE-DAWLEY; YOUNG ADULT;

EID: 84883642207     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.08.019     Document Type: Article

References (21)

1. G.L. Amidon, H. Lennernäs, and V.P. Shah A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
2. P. Artursson, and J. Karlsson Correlation between oral absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Commun. 175 3 1991 880 885
3. A.H. Dantzig, and L. Bergin Uptake of the cephalosporin, cephalexin, by a peptide transport carrier in the human intestinal cell line, Caco-2 Biochim. Biophys. Acta 1027 3 1990 211 217 (Pubitemid 20279132)
4. B. Davies, and T. Morris Physiological parameters in laboratory animals and humans Pharm. Res. 10 7 1993 1093 1095 (Pubitemid 23211439)
5. R.C. Garner Practical experience of using human microdosing with accelerator mass spectrometry analysis to obtain early human drug metabolism and pharmacokinetic data Bioanalysis 2 2010 429 440
6. N. Kaplan, and B. Hafkin In vitro and in vivo absorption properties of AFN-1252, a novel specific-spectrum anti-staphylococcal agent. In: Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Poster F1-2005 2009 American Society for Microbiology Washington, DC, USA
7. N. Kaplan, and B. Hafkin Tolerability, safety and pharmacokinetics of multiple oral doses of AFN-1252 in healthy subjects Abstracts of the Fifty first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract F1-1349 2011 American Society for Microbiology Washington, DC, USA
8. N. Kaplan, H. Flanner, and B. Hafkin Correlation of AFN-1252 Phase 0 microdosing and phase 1 pharmacokinetics Abstracts of the Forty ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Abstract F1-2006 2009 American Society for Microbiology Washington, DC, USA
9. N. Kaplan, W.E. Maier, and B. Hafkin The effect of food on the oral bioavailability of AFN-1252 in healthy human subjects Abstracts of the Twenty first European Congress on Clinical Microbiology and Infectious Diseases, Milan, 2011. Abstract F-1517 2011 European Society of Clinical Microbiology and Infectious Diseases Basel, Switzerland
10. N. Kaplan, M. Albert, and D. Awrey AFN-1252 - mode of action, in vitro activity and in vivo efficacy of AFN-1252, a selective anti-staphylococcal FabI inhibitor Antimicrob. Agents Chemother. 56 11 2012 5865 5874
11. N. Kaplan, D. Awrey, and E. Bardouniotis In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics J. Chemother. 25 1 2013 18 25
12. J.A. Karlowsky, N.M. Laing, and T. Baudry In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis Antimicrob. Agents Chemother. 51 4 2007 1580 1581 (Pubitemid 46586859)
13. J.A. Karlowsky, N. Kaplan, and B. Hafkin AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity Antimicrob. Agents Chemother. 53 8 2009 3544 3548
14. 14C-accelerator mass spectrometry applications Anal. Chem. 83 9 2011 3312 3318
15. J.W. Polli, and C.J. Serabjit-Singh In vitro cell-based assays for estimating the effects of efflux transporters on cell permeation R. Borchardt, E. Kerns, C. Lipinski, D. Thakker, B. Wang, Pharmaceutical Profiling in Drug Discovery for Lead Selection 2005 Springer Berlin 235 256
16. M. Rowland Microdosing: a critical assessment of human data J. Pharm. Sci. 101 2012 4067 4074
17. W. Rubas, N. Jezyk, and G.M. Grass Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption Pharm. Res. 10 1 1993 113 118 (Pubitemid 23020847)
18. P. Shah, V. Jogani, and T. Bagchi Role of Caco-2 cell monolayers in prediction of intestinal drug absorption Biotechnol. Prog. 22 1 2006 186 198 (Pubitemid 43221545)
19. S. Yamashita, Y. Tanaka, and Y. Endoh Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption Pharm. Res. 14 4 1997 486 491 (Pubitemid 27205009)
20. G. Young, S. Corless, and C. Felgate Comparison of a 250 kV single-stage accelerator mass spectrometer - fitness for purpose in bioanalysis Rapid Commun. Mass Spectrom. 22 2008 4035 4042
21. P. Zakeri-Milani, H. Valizadeh, and H. Tajerzadeh Predicting human intestinal permeability using single-pass intestinal perfusion in rat J. Pharm. Pharmaceut. Sci. 10 3 2007 368 379 (Pubitemid 350065177)